Do analysts rate SLS or FRX?

Solaris Resources presently has a consensus price target of C$19.50, indicating a potential upside of 80.72%. Given Solaris Resources' higher possible upside, equities research analysts clearly believe Solaris Resources is more favorable than Fennec Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Solaris Resources 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Fennec Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 4.00

Do analysts rate CARA or FRX?

Given Cara Operations' higher probable upside, research analysts clearly believe Cara Operations is more favorable than Fennec Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cara Operations 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Fennec Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 4.00

Which has higher earnings & valuation, CARA or FRX?

Cara Operations has higher earnings, but lower revenue than Fennec Pharmaceuticals. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cara Operations N/A N/A N/A N/A N/A Fennec Pharmaceuticals C$51.00M 9.69 -C$800.44K -C$0.29 N/A

Do analysts rate CRON or FRX?

Cronos Group currently has a consensus target price of C$4.75, suggesting a potential upside of 19.65%. Given Cronos Group's higher probable upside, analysts plainly believe Cronos Group is more favorable than Fennec Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cronos Group 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 Fennec Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 4.00

Which has preferable valuation & earnings, CRON or FRX?

Fennec Pharmaceuticals has lower revenue, but higher earnings than Cronos Group. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cronos Group C$159.54M 9.30 -C$32.78M N/A N/A Fennec Pharmaceuticals C$51.00M 9.69 -C$800.44K -C$0.29 N/A

Do analysts recommend TLRY or FRX?

Tilray Brands presently has a consensus price target of C$13.30, suggesting a potential upside of 142.26%. Given Tilray Brands' higher possible upside, equities analysts clearly believe Tilray Brands is more favorable than Fennec Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Tilray Brands 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Fennec Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 4.00

Do analysts rate FRX or ITH?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Fennec Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 4.00 International Tower Hill Mines 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Fennec Pharmaceuticals (FRX) Competitors

C$14.22 0.00 (0.00%)

As of 07/22/2026

Compare

FRX vs. SLS, CARA, CRON, TLRY, and ITH

Should you buy Fennec Pharmaceuticals stock or one of its competitors? MarketBeat compares Fennec Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Fennec Pharmaceuticals include Solaris Resources (SLS), Cara Operations (CARA), Cronos Group (CRON), Tilray Brands (TLRY), and International Tower Hill Mines (ITH). These companies are all part of the "pharmaceutical products" industry.

How does Fennec Pharmaceuticals compare to Solaris Resources?

Solaris Resources (TSE:SLS) and Fennec Pharmaceuticals (TSE:FRX) are both small-cap pharmaceutical products companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, dividends, risk, earnings, analyst recommendations, media sentiment, valuation and profitability.

Solaris Resources presently has a consensus price target of C$19.50, indicating a potential upside of 80.72%. Given Solaris Resources' higher possible upside, equities research analysts clearly believe Solaris Resources is more favorable than Fennec Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Solaris Resources	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
Fennec Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	4.00

Fennec Pharmaceuticals has higher revenue and earnings than Solaris Resources. Solaris Resources is trading at a lower price-to-earnings ratio than Fennec Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Solaris Resources	N/A	N/A	-C$46.49M	-C$0.19	N/A
Fennec Pharmaceuticals	C$51.00M	9.69	-C$800.44K	-C$0.29	N/A

In the previous week, Solaris Resources' average media sentiment score of 0.00 equaled Fennec Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
Solaris Resources	Neutral
Fennec Pharmaceuticals	Neutral

Solaris Resources has a beta of 1.777576, meaning that its stock price is 78% more volatile than the broader market. Comparatively, Fennec Pharmaceuticals has a beta of 3.522795, meaning that its stock price is 252% more volatile than the broader market.

16.5% of Solaris Resources shares are held by institutional investors. Comparatively, 14.4% of Fennec Pharmaceuticals shares are held by institutional investors. 40.6% of Solaris Resources shares are held by company insiders. Comparatively, 16.2% of Fennec Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Solaris Resources has a net margin of 0.00% compared to Fennec Pharmaceuticals' net margin of -17.22%. Solaris Resources' return on equity of 60.97% beat Fennec Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Solaris Resources	N/A	60.97%	-51.67%
Fennec Pharmaceuticals	-17.22%	-58.09%	8.88%

Summary

Solaris Resources and Fennec Pharmaceuticals tied by winning 7 of the 14 factors compared between the two stocks.

How does Fennec Pharmaceuticals compare to Cara Operations?

Cara Operations (TSE:CARA) and Fennec Pharmaceuticals (TSE:FRX) are both small-cap pharmaceutical products companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, dividends, media sentiment, risk, profitability, earnings and institutional ownership.

Given Cara Operations' higher probable upside, research analysts clearly believe Cara Operations is more favorable than Fennec Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cara Operations	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Fennec Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	4.00

14.4% of Fennec Pharmaceuticals shares are owned by institutional investors. 16.2% of Fennec Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Cara Operations has a net margin of 0.00% compared to Fennec Pharmaceuticals' net margin of -17.22%. Cara Operations' return on equity of 0.00% beat Fennec Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cara Operations	N/A	N/A	N/A
Fennec Pharmaceuticals	-17.22%	-58.09%	8.88%

Cara Operations has higher earnings, but lower revenue than Fennec Pharmaceuticals.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cara Operations	N/A	N/A	N/A	N/A	N/A
Fennec Pharmaceuticals	C$51.00M	9.69	-C$800.44K	-C$0.29	N/A

In the previous week, Cara Operations' average media sentiment score of 0.00 equaled Fennec Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
Cara Operations	Neutral
Fennec Pharmaceuticals	Neutral

Summary

Fennec Pharmaceuticals beats Cara Operations on 6 of the 9 factors compared between the two stocks.

How does Fennec Pharmaceuticals compare to Cronos Group?

Cronos Group (TSE:CRON) and Fennec Pharmaceuticals (TSE:FRX) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, risk, valuation, profitability, earnings, institutional ownership, dividends and media sentiment.

4.3% of Cronos Group shares are owned by institutional investors. Comparatively, 14.4% of Fennec Pharmaceuticals shares are owned by institutional investors. 46.4% of Cronos Group shares are owned by company insiders. Comparatively, 16.2% of Fennec Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Cronos Group has a net margin of -1.29% compared to Fennec Pharmaceuticals' net margin of -17.22%. Cronos Group's return on equity of -0.19% beat Fennec Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cronos Group	-1.29%	-0.19%	-3.73%
Fennec Pharmaceuticals	-17.22%	-58.09%	8.88%

Cronos Group currently has a consensus target price of C$4.75, suggesting a potential upside of 19.65%. Given Cronos Group's higher probable upside, analysts plainly believe Cronos Group is more favorable than Fennec Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cronos Group	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00
Fennec Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	4.00

Fennec Pharmaceuticals has lower revenue, but higher earnings than Cronos Group.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cronos Group	C$159.54M	9.30	-C$32.78M	N/A	N/A
Fennec Pharmaceuticals	C$51.00M	9.69	-C$800.44K	-C$0.29	N/A

In the previous week, Cronos Group's average media sentiment score of 0.00 equaled Fennec Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
Cronos Group	Neutral
Fennec Pharmaceuticals	Neutral

Cronos Group has a beta of 1.126226, meaning that its stock price is 13% more volatile than the broader market. Comparatively, Fennec Pharmaceuticals has a beta of 3.522795, meaning that its stock price is 252% more volatile than the broader market.

Summary

Fennec Pharmaceuticals beats Cronos Group on 8 of the 14 factors compared between the two stocks.

How does Fennec Pharmaceuticals compare to Tilray Brands?

Tilray Brands (TSE:TLRY) and Fennec Pharmaceuticals (TSE:FRX) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, analyst recommendations, risk, institutional ownership, media sentiment, valuation, dividends and profitability.

Fennec Pharmaceuticals has lower revenue, but higher earnings than Tilray Brands. Fennec Pharmaceuticals is trading at a lower price-to-earnings ratio than Tilray Brands, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tilray Brands	C$858.28M	0.79	-C$183.24M	-C$14.63	N/A
Fennec Pharmaceuticals	C$51.00M	9.69	-C$800.44K	-C$0.29	N/A

In the previous week, Tilray Brands had 2 more articles in the media than Fennec Pharmaceuticals. MarketBeat recorded 2 mentions for Tilray Brands and 0 mentions for Fennec Pharmaceuticals. Fennec Pharmaceuticals' average media sentiment score of 0.00 beat Tilray Brands' score of -0.02 indicating that Fennec Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
Tilray Brands	Neutral
Fennec Pharmaceuticals	Neutral

Tilray Brands presently has a consensus price target of C$13.30, suggesting a potential upside of 142.26%. Given Tilray Brands' higher possible upside, equities analysts clearly believe Tilray Brands is more favorable than Fennec Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tilray Brands	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Fennec Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	4.00

Fennec Pharmaceuticals has a net margin of -17.22% compared to Tilray Brands' net margin of -158.75%. Fennec Pharmaceuticals' return on equity of -58.09% beat Tilray Brands' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tilray Brands	-158.75%	-88.06%	-1.41%
Fennec Pharmaceuticals	-17.22%	-58.09%	8.88%

4.2% of Tilray Brands shares are held by institutional investors. Comparatively, 14.4% of Fennec Pharmaceuticals shares are held by institutional investors. 0.7% of Tilray Brands shares are held by insiders. Comparatively, 16.2% of Fennec Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Tilray Brands has a beta of 3.0845, meaning that its stock price is 208% more volatile than the broader market. Comparatively, Fennec Pharmaceuticals has a beta of 3.522795, meaning that its stock price is 252% more volatile than the broader market.

Summary

Fennec Pharmaceuticals beats Tilray Brands on 12 of the 16 factors compared between the two stocks.

How does Fennec Pharmaceuticals compare to International Tower Hill Mines?

Fennec Pharmaceuticals (TSE:FRX) and International Tower Hill Mines (TSE:ITH) are both small-cap pharmaceutical products companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, valuation, dividends, earnings, risk, media sentiment, analyst recommendations and institutional ownership.

International Tower Hill Mines has a net margin of 0.00% compared to Fennec Pharmaceuticals' net margin of -17.22%. International Tower Hill Mines' return on equity of -1.99% beat Fennec Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Fennec Pharmaceuticals	-17.22%	-58.09%	8.88%
International Tower Hill Mines	N/A	-1.99%	-3.65%

14.4% of Fennec Pharmaceuticals shares are held by institutional investors. Comparatively, 9.2% of International Tower Hill Mines shares are held by institutional investors. 16.2% of Fennec Pharmaceuticals shares are held by company insiders. Comparatively, 0.5% of International Tower Hill Mines shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Fennec Pharmaceuticals has higher revenue and earnings than International Tower Hill Mines. International Tower Hill Mines is trading at a lower price-to-earnings ratio than Fennec Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Fennec Pharmaceuticals	C$51.00M	9.69	-C$800.44K	-C$0.29	N/A
International Tower Hill Mines	N/A	N/A	-C$2.36M	-C$0.01	N/A

In the previous week, Fennec Pharmaceuticals' average media sentiment score of 0.00 equaled International Tower Hill Mines'average media sentiment score.

Company	Overall Sentiment
Fennec Pharmaceuticals	Neutral
International Tower Hill Mines	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Fennec Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	4.00
International Tower Hill Mines	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Fennec Pharmaceuticals has a beta of 3.522795, suggesting that its stock price is 252% more volatile than the broader market. Comparatively, International Tower Hill Mines has a beta of 2.361834, suggesting that its stock price is 136% more volatile than the broader market.

Summary

Fennec Pharmaceuticals beats International Tower Hill Mines on 9 of the 12 factors compared between the two stocks.

Get Fennec Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding FRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of TSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

FRX vs. The Competition

Export

Metric	Fennec Pharmaceuticals	Biotechnology Industry	Medical Sector	TSE Exchange
Market Cap	C$493.96M	C$441.23M	C$6.88B	C$12.48B
Dividend Yield	2.02%	3.90%	2.67%	6.19%
P/E Ratio	-49.03	3.16	27.00	36.95
Price / Sales	9.69	6,592.20	491.80	9.44
Price / Cash	11.66	13.13	50.54	82.29
Price / Book	12.99	83.70	10.28	4.39
Net Income	-C$800.44K	-C$96.07M	C$3.60B	C$299.09M
7 Day Performance	N/A	-0.51%	-1.25%	0.61%
1 Month Performance	-5.20%	-0.94%	-0.35%	1.06%
1 Year Performance	18.60%	56.41%	18.41%	30.89%

Fennec Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count
FRX Fennec Pharmaceuticals	N/A	C$14.22 flat	N/A	N/A	C$493.96M	C$51.00M	N/A	10
SLS Solaris Resources	1.419 of 5 stars	C$9.94 -2.3%	C$19.50 +96.2%	+56.6%	C$1.66B	N/A	N/A	10
CARA Cara Operations	N/A	N/A	N/A	N/A	C$1.62B	N/A	N/A	80
CRON Cronos Group	1.9672 of 5 stars	C$3.92 +1.0%	C$4.75 +21.2%	+40.8%	C$1.46B	C$159.54M	N/A	450
TLRY Tilray Brands	1.3425 of 5 stars	C$6.06 -0.8%	C$13.30 +119.5%	-43.4%	C$748.15M	C$858.28M	N/A	2,650

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (TSE:FRX) was last updated on 7/25/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Fennec Pharmaceuticals (FRX) Competitors

FRX vs. SLS, CARA, CRON, TLRY, and ITH

How does Fennec Pharmaceuticals compare to Solaris Resources?

Summary

How does Fennec Pharmaceuticals compare to Cara Operations?

Summary

How does Fennec Pharmaceuticals compare to Cronos Group?

Summary

How does Fennec Pharmaceuticals compare to Tilray Brands?

Summary

How does Fennec Pharmaceuticals compare to International Tower Hill Mines?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

FRX vs. The Competition

Fennec Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Fennec Pharmaceuticals (FRX) Competitors

FRX vs. SLS, CARA, CRON, TLRY, and ITH

How does Fennec Pharmaceuticals compare to Solaris Resources?

Do analysts rate SLS or FRX?

Which has higher valuation & earnings, SLS or FRX?

Does the media refer more to SLS or FRX?

Which has more risk & volatility, SLS or FRX?

Do institutionals & insiders believe in SLS or FRX?

Is SLS or FRX more profitable?

Summary

How does Fennec Pharmaceuticals compare to Cara Operations?

Do analysts rate CARA or FRX?

Do insiders & institutionals hold more shares of CARA or FRX?

Is CARA or FRX more profitable?

Which has higher earnings & valuation, CARA or FRX?

Does the media refer more to CARA or FRX?

Summary

How does Fennec Pharmaceuticals compare to Cronos Group?

Do insiders and institutionals hold more shares of CRON or FRX?

Is CRON or FRX more profitable?

Do analysts rate CRON or FRX?

Which has preferable valuation & earnings, CRON or FRX?

Does the media prefer CRON or FRX?

Which has more risk and volatility, CRON or FRX?

Summary

How does Fennec Pharmaceuticals compare to Tilray Brands?

Which has better valuation & earnings, TLRY or FRX?

Does the media prefer TLRY or FRX?

Do analysts recommend TLRY or FRX?

Is TLRY or FRX more profitable?

Do institutionals & insiders hold more shares of TLRY or FRX?

Which has more volatility & risk, TLRY or FRX?

Summary

How does Fennec Pharmaceuticals compare to International Tower Hill Mines?

Is FRX or ITH more profitable?

Do insiders & institutionals have more ownership in FRX or ITH?

Which has preferable earnings and valuation, FRX or ITH?

Does the media favor FRX or ITH?

Do analysts rate FRX or ITH?

Which has more volatility and risk, FRX or ITH?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

FRX vs. The Competition

Fennec Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools